Alebund Pharma (HKG: 9637) announced that its lead drug candidate, AP308, has received U.S. Food...
Alebund Pharmaceuticals (Jiangsu) Limited (HKG: 9637) announced that the New Drug Application (NDA) for its core...
Alebund Pharmaceuticals (HKG: 9637) announced that the first patient has been randomized and dosed in...
Alebund Pharmaceuticals (Jiangsu) Limited (HKG: 9637) successfully completed its initial public offering (IPO) on the...
Alebund Pharmaceuticals, a Shanghai-based biopharmaceutical company focused on kidney disease therapeutics, has filed its prospectus...
Alebund Pharmaceuticals has entered into an exclusive licensing agreement with R1 Therapeutics, Inc. (UK) for...
Shanghai-based Alebund Pharmaceuticals has announced the completion of a Series C financing round, raising RMB...
Alebund Pharmaceuticals, based in Shanghai, has announced that its drug candidate AP306 (EOS789), a pan-inhibitor...
Shanghai-based Alebund Pharmaceuticals has entered into a commercialization agreement with Swiss pharmaceutical giant Roche (SWX:...
Shanghai-based Alebund Pharmaceuticals has announced the completion of a pre-Series C financing round worth RMB...